BWXT (BWXT) Q2 2026 Earnings Call Transcript
BWX Technologies (NYSE:BWXT) reported Q2 2026 revenue of $901.6 million, up 18%, with adjusted EBITDA of $155.5 million (+7%) and non-GAAP EPS of $1.07 (+5%). Backlog rose to $8.4 billion (+40%). Full-year guidance was raised, including revenue to about $3.8 billion and adjusted EBITDA to $662-$672 million. BWXT also agreed to sell about 80% of its medical business for up to $800 million.
How this was made
The 30-second read
Why it matters
The key tradable items are the raised 2026 guidance across revenue, adjusted EBITDA, EPS, and free cash flow, alongside a medical business sale (up to $800M) and the closed Precision Components Group acquisition. These can drive estimate revisions and sentiment, while margin and order-timing uncertainties can temper the reaction.
Market read
Guidance raises plus major corporate actions (medical sale, PCG acquisition) are likely to be the primary drivers for near-term positioning in BWXT.
What to watch
Backlog growth and book-to-bill are supportive, but the company flagged uncertainty around timing of new-build nuclear equipment orders by year-end, which can affect quarter-to-quarter revenue conversion.
Background
BWX Technologies’ Q2 2026 earnings call covers commercial nuclear power and nuclear medicine expansion, defense-related government operations, and capital allocation moves including a medical business sale and a commercial nuclear manufacturing acquisition.
Ticker impact
BWX Technologies raised 2026 revenue, adjusted EBITDA, EPS, and free cash flow guidance, citing PCG integration and U.S. capacity investments.
Likely positive bias for the next few sessions as traders digest the guidance raises and capital allocation shift.
The article provides multiple quantified guidance revisions (revenue, EBITDA, EPS, FCF) and concrete corporate actions (medical sale up to $800M, PCG acquisition closed July 1), which are actionable for positioning. However, it is a transcript summary and may not include all details that could affect estimates.
Market effects
Reinforces the narrative of a multi-decade nuclear build cycle, supporting sentiment for U.S. nuclear supply chain names.
U.S. manufacturing capacity expansion and Navy shipbuilding cadence highlight continued defense-related demand concentration in the U.S.
Commercial nuclear power and nuclear medicine growth signals demand beyond defense, potentially affecting global reactor and fuel-cycle supply expectations.
Counterpoint
Commercial Operations margin guidance was revised downward due to incremental scaling investments, which could cap near-term upside despite revenue growth.
Key entities
- companyBWX Technologies, Inc.
Reported Q2 2026 results and raised full-year 2026 guidance; announced medical business sale and discussed PCG integration and nuclear program milestones.
- private_firmNordic Capital
Named as the buyer for up to 80% of BWXT’s medical business, with valuation up to $800M.
- business_unitPrecision Components Group (PCG)
Commercial nuclear manufacturing platform acquired by BWXT, closed July 1, 2026.
